Categories: BrainNews

NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022

MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 11, 2022. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com.

An archived recording will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com. The webcasts will be available for replay for at least 90 days after the event.

About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
investors@neuropace.com 

Staff

Recent Posts

FendX Announces Fifth Real-World Testing Site for REPELWRAP(TM) Film with New Vista Society, a Long-Term Care and Senior Housing Provider

Testing nanotechnology to assess for further optimization of manufacturing process at DunmoreOakville, Ontario--(Newsfile Corp. -…

2 hours ago

Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease

Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings…

3 hours ago

Twenty Percent Of The World’s Employees Experience Loneliness While Global Employee Engagement Stagnated And Employee Wellbeing Declined

WASHINGTON, June 12, 2024 /PRNewswire/ -- Gallup's latest State of the Global Workplace report finds that…

3 hours ago

Alida Biosciences Announces Series A Funding and Early Access Launch of Innovative Products for Epitranscriptomic Research

SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools,…

3 hours ago

ScandiNova joins the United Nations Global Compact

UPPSALA, Sweden, June 12, 2024 /PRNewswire/ -- ScandiNova Group is proud to announce its participation…

3 hours ago